CDKN2A and glioma: Notably, deletion, mutation or hypermethylation of CDKN2A/2B are frequently observed in head and neck cancer, non-small cell lung cancer (NSCLC), prostate adenocarcinoma (PRAD), glioma, esophageal carcinoma, bladder cancer and T-cell lymphoma [2–8].